Soleus Capital Management, L.P. 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Soleus Capital Management, L.P. disclosed 87 US equity positions worth $1.9bn in its Q3 2025 13F filing. The largest position was KRYS at 9.6% of the reported book, followed by TGTX and NVCR. Against the Q2 2025 filing, it opened 8 new positions, added to 23 and reduced 14 among the top 50 holdings.
What did Soleus Capital Management, L.P. own in Q3 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | KRYS KRYSTAL BIOTECH INC | Healthcare | 9.6% | $179.9m | 1,018,831 | 10% | added |
| 2 | TGTX TG THERAPEUTICS INC | Healthcare | 7.4% | $138.9m | 3,844,731 | 71% | added |
| 3 | NVCR NOVOCURE LTD | Healthcare | 6.7% | $124.6m | 9,644,872 | 40% | added |
| 4 | ELV ELEVANCE HEALTH INC FORMERLY | Healthcare | 4.5% | $83.9m | 259,650 | 271% | added |
| 5 | BBNX BETA BIONICS INC | Healthcare | 4.1% | $76.9m | 3,870,158 | 1% | added |
| 6 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 3.4% | $62.9m | 150,000 | -29% | reduced |
| 7 | 430 TERNS PHARMACEUTICALS INC | 3.3% | $61.0m | 8,127,100 | -0% | held | |
| 8 | CELC CELCUITY INC | Healthcare | 3.1% | $58.2m | 1,178,860 | -61% | reduced |
| 9 | INSP INSPIRE MED SYS INC | Healthcare | 2.9% | $54.0m | 728,188 | 568% | added |
| 10 | TWST TWIST BIOSCIENCE CORP | Healthcare | 2.8% | $52.5m | 1,866,234 | 427% | added |
| 11 | ARGX ARGENX SE | Healthcare | 2.7% | $51.2m | 69,426 | 62% | added |
| 12 | ORGO ORGANOGENESIS HLDGS INC | Healthcare | 2.7% | $51.2m | 12,131,699 | -2% | reduced |
| 13 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 2.6% | $48.2m | 890,304 | -1% | reduced |
| 14 | CDTX CIDARA THERAPEUTICS INC | 2.5% | $47.3m | 493,811 | 7% | added | |
| 15 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.4% | $45.5m | 859,166 | -11% | reduced |
| 16 | AM6 AMICUS THERAPEUTICS INC | 2.0% | $37.0m | 4,690,000 | – | new | |
| 17 | INDIVIOR PLC | 1.9% | $35.3m | 1,466,000 | – | new | |
| 18 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.7% | $31.3m | 68,336 | 754% | added |
| 19 | ANIP ANI PHARMACEUTICALS INC | Healthcare | 1.7% | $31.2m | 340,243 | 571% | added |
| 20 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.7% | $31.0m | 2,012,110 | 84% | added |
| 21 | AXGN AXOGEN INC | Healthcare | 1.6% | $30.8m | 1,726,553 | 18% | added |
| 22 | NPCE NEUROPACE INC | 1.6% | $30.5m | 2,957,957 | 28% | added | |
| 23 | GRFS GRIFOLS S A | Healthcare | 1.3% | $24.9m | 2,500,000 | -57% | reduced |
| 24 | GERN GERON CORP | Healthcare | 1.3% | $23.7m | 17,290,000 | 7% | added |
| 25 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.2% | $22.4m | 2,422,833 | 0% | held |
| 26 | IART INTEGRA LIFESCIENCES HLDGS C | Healthcare | 1.1% | $20.6m | 1,440,818 | 4% | added |
| 27 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.0% | $19.4m | 138,000 | – | new |
| 28 | ANAB ANAPTYSBIO INC | Healthcare | 1.0% | $19.2m | 626,040 | 95% | added |
| 29 | EDAP TMS S A | 0.9% | $16.7m | 7,309,254 | 0% | held | |
| 30 | PHVS PHARVARIS N V | 0.9% | $16.1m | 647,052 | -12% | reduced | |
| 31 | VCEL VERICEL CORP | Healthcare | 0.8% | $15.7m | 497,953 | 877% | added |
| 32 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.8% | $15.7m | 7,053,942 | 1% | added |
| 33 | BLTE BELITE BIO INC | Healthcare | 0.8% | $15.5m | 210,000 | – | new |
| 34 | VCYT VERACYTE INC | Healthcare | 0.8% | $14.5m | 422,055 | -41% | reduced |
| 35 | RAPT RAPT THERAPEUTICS INC | 0.7% | $13.9m | 537,903 | – | new | |
| 36 | URGN UROGEN PHARMA LTD | Healthcare | 0.7% | $13.5m | 679,000 | -69% | reduced |
| 37 | STAA STAAR SURGICAL CO | Healthcare | 0.7% | $13.4m | 500,000 | -83% | reduced |
| 38 | SION SIONNA THERAPEUTICS INC | 0.6% | $12.2m | 413,500 | 10% | added | |
| 39 | CGON CG ONCOLOGY INC | Healthcare | 0.6% | $11.7m | 290,000 | 87% | added |
| 40 | QURE UNIQURE NV | 0.6% | $11.7m | 200,000 | – | new | |
| 41 | QDEL QUIDELORTHO CORP | Healthcare | 0.6% | $11.0m | 375,000 | 116% | added |
| 42 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 0.6% | $10.9m | 148,696 | -50% | reduced |
| 43 | ADMA ADMA BIOLOGICS INC | Healthcare | 0.6% | $10.8m | 738,000 | 322% | added |
| 44 | IKT INHIBIKASE THERAPEUTICS INC | 0.5% | $10.2m | 6,325,000 | 0% | held | |
| 45 | GMED GLOBUS MED INC | Healthcare | 0.5% | $10.1m | 176,000 | – | new |
| 46 | GSK GSK PLC | Healthcare | 0.5% | $9.5m | 220,000 | – | new |
| 47 | RIGL RIGEL PHARMACEUTICALS INC | 0.5% | $9.3m | 330,010 | -50% | reduced | |
| 48 | EOLS EVOLUS INC | Healthcare | 0.5% | $8.9m | 1,450,000 | -32% | reduced |
| 49 | VSTM VERASTEM INC | Healthcare | 0.4% | $8.3m | 935,909 | 0% | held |
| 50 | ACLXGBX ARCELLX INC | 0.4% | $8.2m | 100,000 | -19% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.